These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 3137401)

  • 41. [Monoclonal gammopathy of undetermined significance].
    Hermansen NEU; Silkjær T; Hansen CT; Aagaard TG; Gregersen H
    Ugeskr Laeger; 2020 Mar; 182(10):. PubMed ID: 32138824
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epidemiology of monoclonal gammopathy in Morocco - A hospital-based study.
    Ouzzif Z; Doghmi K; Messaoudi N; Bouhsain S; El Machtani S; Biaz A; Rachid A; Dami A; Bezza A; El Maataoui A
    Cancer Rep (Hoboken); 2023 May; 6(5):e1814. PubMed ID: 36999311
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential diagnosis of monoclonal gammopathy of undetermined significance.
    Merlini G; Palladini G
    Hematology Am Soc Hematol Educ Program; 2012; 2012():595-603. PubMed ID: 23233640
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
    Kyle RA; Therneau TM; Rajkumar SV; Offord JR; Larson DR; Plevak MF; Melton LJ
    N Engl J Med; 2002 Feb; 346(8):564-9. PubMed ID: 11856795
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Monoclonal gammopathy of undetermined significance].
    Chaïbi P; Merlin L; Thomas C; Piette F
    Ann Med Interne (Paris); 2002 Nov; 153(7):459-66. PubMed ID: 12598832
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Neurologic manifestations of monoclonal gammapathies].
    Uldry PA; Steck AJ; Regli F
    Schweiz Med Wochenschr; 1984 Nov; 114(47):1678-85. PubMed ID: 6096963
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
    Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
    Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Malignant transformation of monoclonal gammopathy of undetermined significance].
    Decaux O; Avet-Loiseau H; Grosbois B
    Presse Med; 2007 Dec; 36(12 Pt 3):1985-96. PubMed ID: 17509811
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oligoclonal gammopathy: An analysis of 253 cases.
    Karaszewski K; Jasiński M; Waszczuk-Gajda A; Rodziewicz-Lurzyńska A; Ciepiela O; Jędrzejczak WW
    Adv Clin Exp Med; 2024 Feb; 33(2):127-134. PubMed ID: 37341173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monoclonal gammopathy and spurious hypophosphatemia.
    Weisbord SD; Chaudhuri A; Blauth K; DeRubertis FR
    Am J Med Sci; 2003 Feb; 325(2):98-100. PubMed ID: 12589234
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuropathy and monoclonal gammopathy.
    Nobile-Orazio E
    Handb Clin Neurol; 2013; 115():443-59. PubMed ID: 23931795
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurologic aspects of plasma cell disorders.
    Sobol U; Stiff P
    Handb Clin Neurol; 2014; 120():1083-99. PubMed ID: 24365373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Experiences in the diagnosis and treatment of polyneuropathies in patients with malignant monoclonal gammopathy].
    Baumann I; Krause T; Schwenke H; Lehmann J
    Psychiatr Neurol Med Psychol (Leipz); 1990 Feb; 42(2):85-95. PubMed ID: 2158116
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Monoclonal gammopathy of (un)known significance].
    Steinhardt M; Kortüm M; Einsele H; Rasche L
    Dtsch Med Wochenschr; 2022 Jun; 147(11):675-682. PubMed ID: 35636418
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenström's macroglobulinemia (SWM).
    Kyle RA; Dispenzieri A; Kumar S; Larson D; Therneau T; Rajkumar SV
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):74-6. PubMed ID: 21454195
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.
    Katzmann JA; Abraham RS; Dispenzieri A; Lust JA; Kyle RA
    Clin Chem; 2005 May; 51(5):878-81. PubMed ID: 15774572
    [TBL] [Abstract][Full Text] [Related]  

  • 57. T-cell subpopulations in patients with monoclonal gammopathies: essential monoclonal gammopathy, multiple myeloma, and Waldenstrom macroglobulinemia.
    San Miguel JF; Caballero MD; Gonzalez M
    Am J Hematol; 1985 Nov; 20(3):267-73. PubMed ID: 3933332
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incidental finding of monoclonal gammopathy in blood donors: a follow-up study.
    La Raja M; Barcobello M; Bet N; Dolfini P; Florean M; Tomasella F; De Angelis V; Mascaretti L
    Blood Transfus; 2012 Jul; 10(3):338-43. PubMed ID: 22507857
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study.
    Kaplan B; Golderman S; Aizenbud B; Esev K; Kukuy O; Leiba M; Livneh A; Ben-Zvi I
    Am J Hematol; 2014 Sep; 89(9):882-8. PubMed ID: 24866208
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monoclonal gammopathy: The good, the bad and the ugly.
    Glavey SV; Leung N
    Blood Rev; 2016 May; 30(3):223-31. PubMed ID: 26732417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.